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Cervical cancer (CaCx) is one of the leading causes of death among
Indian women, contributing to one-fourth of the global total of deaths
incurred due to this. Recent reports (http://www-dep.iarc.fr/) depict
that 132,082 new cases and 74,118 deaths are recorded every year
(age-standardized rates: incidence=30.7; mortality=17.8) in India.
While HPV infections appear to be the major etiological factors for
CaCx development (Schlecht et al., 2001), HPV16 is the most common
high-risk type identiﬁed among such cases both worldwide (Munoz
et al., 2003) aswell as in India (De Andrea et al., 2007; Franceschi et al.,
2005; Laikangbam et al., 2007; Sowjanya et al., 2005). Majority of HPV
infections regress spontaneously. Only a small percentage of high-risk
HPV-infected women harbor persistent infections that lead to cervical
carcinogenesis, after a long latent period. This points to the need of
HPV testing and the identiﬁcation of HPV-related cofactors that might
be relevant for detecting those at risk of developing CaCx in the long
run.
It is known that viral genome in episomal form replicates along with
the differentiating epithelial cells from basal membrane to the superﬁcial
zoneand is shedoff alongwith the sloughed-off epithelial cells resulting in
transient infection (zur Hausen, 2002). Persistent infection and viral
genome integration into the host genome is known to mediate
oncogenicity (Woodman et al., 2007). E1 and E2 are the early viralproteins needed for viral replication and translation, while E6 and E7 are
the oncoproteins responsible for cellular transformation by inactivation of
p53 and pRb proteins, respectively. E2 protein represses E6 and E7
expression. Integration of viral genome into the host genome, chieﬂy at
fragile sites (Kalantari et al., 2001; Wentzensen et al., 2004), not only
affects various cellular pathways of the host cell-cyclemachinery, but also
disrupts the viral E2 gene most commonly in the hinge region of the
HPV16 E2 protein. In absence of E2-driven repression, E6 and E7 are over-
expressed driving infected cells toward transformation.
On the contrary, our study (Bhattacharjee and Sengupta, 2006a) as
well as a few others (Narayanan et al., 2004) has identiﬁed that a
substantial proportion of individuals with CaCx harbor intact E2, which
could be either purely intact or concomitant, i.e., a mixture of intact and
disrupted forms. Such observations, point toward the biological
plausibility of cervical carcinogenesis under the impact of HPV16 intact
E2 gene or intact viral genomes, in addition to E2 disruption due to viral
genome integration into the host genome. Many study groups have
proposed viral load estimates per cell or per unit amount of genomic
DNA, as a potential HPV-related biomarker, which could be used for
predicting those at risk of CaCx development (Franco and Coutlée,
2009). However, there are several reports, which have failed to relate
high HPV16 DNA copy number with CaCx development (Swan et al.,
1999; Josefsson et al., 2000; van Duin et al., 2002; Hernandez-
Hernandez et al., 2003; Abba et al., 2003; de Boer et al., 2007).
We undertook the present study to investigate the association of
HPV16 viral load, if any, with CaCx by comparing HPV16 positive
cytologically normal women with those diagnosed with CaCx (squa-
mous cell carcinomas). Apart fromconsidering the potential of viral load
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association with the risk of CaCx in consideration with other factors
related to the viral genome such as (i) disruption or intactness of the
viral E2 gene and (ii) ratios of viral load based on E2 and E6 gene copies,
i.e., E2/E6 ratios. A number of studies (Peitsaro et al., 2002; Cricca et al.,
2007; Saunier et al., 2008) have proposed the latter factor as a reliable
indicator of the physical status of viral genomes within the host cells.
Results
Distribution of viral load among cases and controls
Number of copies of HPV16 viral genome (viral load) per 100 ng of
HPV16 positive genomic DNA (natural log transformed) was
evaluated in 152 cases and 87 controls. The viral load per 100 ng
HPV16 positive genomic DNA was calculated from the standard plot
constructed with various concentrations of HPV16 plasmid DNA per
100 ng genomic DNA, after ampliﬁcation of a portion of HPV16 E6 by
qRT-PCR. Viral load among cases ranged between 3.977 and 22.764, as
shown in Fig. 1, with a median viral load of 17.21. Viral load among
controls ranged between 3.736 and 20.527, with amedian viral load of
9.86. Using Mann–Whitney U test, we identiﬁed that irrespective of
viral E2 gene status (i.e., E2 intact or disrupted), median viral load in
cases (17.21) was signiﬁcantly (p-valueb0.001) higher compared to
that in controls (9.86).
Distribution of different physical forms (intact or disrupted) of E2 gene
among cases and controls
Having conﬁrmed the E2 disruption status as disrupted (pure
disruption) or intact, as per the protocol adopted earlier in our
laboratory (Bhattacharjee and Sengupta, 2006a,b), we undertook the
method of Peitsaro et al. (2002) to determine the proportion of E2
intact samples that were of themixed type, i.e., harbored disruption of
E2 as well as intact E2. As per this protocol (Peitsaro et al., 2002), on
the basis of the ratio of copy numbers of E2 and E6 (E2/E6), the E2
gene is interpreted as intact when E2/E6≥1, mixed or concomitant
forms of intact and disrupted when 0bE2/E6b1, and disrupted when
E2/E6=0, i.e., E2 fails to amplify.
We observed that, out of 152 cases, 139 (91.45%) had intact E2 (22
purely intact and 117 concomitant) and 13 (8.55%) had purely
disrupted E2. Out of 87 controls, 77 (88.5%) had intact E2 (26 purely
intact and 51 concomitant) and 10 (11.49%) had purely disrupted E2.
Case control analysis of this data revealed that while pure E2Fig. 1. Box plots representing distribution of HPV16 viral load (natural log transformed)
per 100 ng genomic DNA among case and control samples.disruption or viral integration failed to show any signiﬁcant difference
between the sample groups, concomitant or mixed forms of E2 or
viral genomes were signiﬁcantly higher among cases compared to
controls (OR=2.71; CI=1.41–5.22; p-value=0.002) among those
identiﬁed with intact E2 by PCRs covering the entire E2. Similar
observation was also recorded, when disrupted and concomitant
forms were grouped together in comparison to the purely intact E2
(OR=2.52; CI=1.32–4.79; p-value=0.004) and case control analy-
sis was performed.Viral load among CaCx cases in consideration of E2 disruption status or
various physical forms of the samples
Based on Mann–Whitney U test, we observed that the cases with
intact E2 (n=139) harbored a signiﬁcantly (pb0.001) higher viral
load (median value=17.80) than those with disrupted E2 (n=13;
median value=9.78). The range of viral load within E2 intact cases
was between 6.376 and 22.764, while that within E2 disrupted cases
was between 9.778 and 19.336. Further analysis of the data revealed
that viral load was signiﬁcantly higher (p=0.001 and pb0.001,
respectively) among CaCx cases having intact E2 or E2/E6≥1 (n=22;
median value=17.053) and those having mixed forms or 0bE2/
E6b1 (n=117; median value=17.930) compared to CaCx cases
having disrupted E2. Among the CaCx cases havingmixed forms of E2,
we determined the HPV16 viral load of the isolates harboring
disrupted E2, by subtracting the copy number of intact E2 from the
total viral load represented by E6. It was observed that the median
viral load of such isolates within the pool of mixed samples was 1.380
(range 0.024–1.907) and this was signiﬁcantly lower (pb0.001)
compared to that of CaCx cases having disrupted E2 only. The
observations indicate a possible association between viral load and
CaCx, which is likely to be inﬂuenced by E2 status (intact or
disrupted).Logistic regression analysis of the association of viral load with CaCx
It was observed that there was a signiﬁcant difference (pb0.001) in
the mean age of CaCx cases (49.60±11.06 years) and that of controls
(33.52±11.014 years). However, the mean age of those CaCx cases
harboring intact E2gene (49.64±11.10 years) failed todiffer (p=0.899)
from those harboring disrupted E2 (49.23±10.12 years). We therefore
determined the potential of viral copy number or load as a risk factor of
HPV16-related CaCx, either independently or by considering it as a
cofactor of disease risk along with E2 disruption status and determined
the ORage-adjusted and p-values, based on logistic regression models. Such
analysis is depicted in Table 1, which revealed that viral load was
signiﬁcantly associated with CaCx [ORage-adjusted=1.261; CI=1.161–
1.369; pb0.001] irrespective of other factors. Logistic regression analysis
considering the twoviral factors as covariates showed that bothviral load
[ORage-adjusted=1.333; CI=1.207–1.472; pb0.001] and E2 disruption
status [ORage-adjusted=5.225; CI=1.426–19.149; p=0.013] were signif-
icantly associated with CaCx.Table 1
Age-based logistic regression analysis of the association of viral load with CaCx either as
an independent risk factor or in consideration of other viral risk factors.
Model
no.
Model variables Regression
coefﬁcient
S.E. p-value OR (95% CI)
1 Age 0.124 0.020 0.000 1.132 (1.089–1.177)
Viral load 0.232 0.042 0.000 1.261 (1.161–1.369)
Constant −7.747 1.078 0.000 0.000
2 Age 0.128 0.021 0.000 1.137 (1.091–1.184)
Viral load 0.287 0.051 0.000 1.333 (1.207–1.472)
E2 disruption status 1.653 0.663 0.013 5.225 (1.426–19.149)
Constant −8.855 1.271 0.000 0.000
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status, and age of subjects
Viral loadand E2 disruption statuswere signiﬁcantly associatedwith
CaCx risk as revealed by the age-adjusted OR (95% CI) and p-values in
Table 1. In addition, there was signiﬁcant difference in mean age
between the CaCx cases and controls, irrespective of E2 disruption
status. Therefore, taking into consideration the effects of all these
explanatory variables, two probability-prediction graphs for the disease
risk were constructed, using the ﬁtted logistic regressionmodels of case
control status on viral load, E2 disruption status, and age. Fig. 2A and B
represents the probability of disease risk for different viral loads at
different ages ranging from 20 to 70 years, in the presence of intact E2
(Fig. 2A) or disrupted E2 (Fig. 2B), respectively. Based on comparative
analysis of Fig. 2A and B, it was evident that the disease risk increased
with increase in viral load and alsowith increase in age of the individual,
irrespective of their E2 disruption status. Moreover, at a particular age,
for any viral load, probability of being classiﬁed as a CaCx case was
higher for individuals harboring disrupted E2 than for those harboringFig. 2. (A) Probability scores (Y-axis) for the disease risk versus viral load (natural log
transformed) per 100 ng genomic DNA (X-axis) among individuals of different ages
harboring intact HPV16 E2 gene: a (age 20 years); b (age 30 years); c (age 40 years);
d (age 50 years); e (age 60 years); f (age 70 years). (B) Probability scores (Y-axis)
for the disease risk versus viral load (natural log transformed) per 100 ng genomic DNA
(X-axis) across different ages, harboring disrupted HPV16 E2 gene: a (age 20 years);
b (age 30 years); c (age 40 years); d (age 50 years); e (age 60 years); f (age 70 years).intact E2. Irrespective of E2 status, at similar risk levels, individuals of
lower age were found to harbor higher viral load, compared to those of
higher age. In addition, at equal risk level and being of similar age, those
harboring intact E2portrayed ahigher viral load compared to thosewith
disrupted E2, as evident from the plots.
Discussion
HPV16 E2 gene disruption, as a consequence of viral integration into
the host genome, is considered as a critical event in the pathogenesis of
cervical neoplasia due to the loss of negative feedback control of viral
oncogene expression (Tan et al., 1994; Jeon and Lambert, 1995). Recent
reports (Narayanan et al., 2004; Anderssen et al., 2005; Cheung et al.,
2006), including one from our laboratory (Bhattacharjee and Sengupta,
2006a) portraying the presence of intact E2 genes in almost 60% of
HPV16 positive CaCx cases, have subsequently paved the way for new
paradigms of cervical carcinogenesis (Bhattacharjee and Sengupta,
2006b; Bhattacharjee et al., 2008). These are directed toward exploring
alternative mechanisms of loss of E2 repression that could lead to
sustainedE6/E7expressionevenwith intact E2 gene, i.e., in thepresence
of concomitant viral genomes (both episomal and integrated) or purely
episomal viral genomes.
Apart from viral integration status or the status of viral E2 genes
(intact or disrupted), other HPV-related factors are also being considered
for predicting the risk of CaCx and viral load appears to be one such factor.
We, therefore, estimated the viral load of HPV16 in our samples (cases
and controls) on the basis of E6 copy numbers irrespective of other viral
factors or taking into consideration the status of E2 (intact or disrupted).
Our study reﬂected a signiﬁcant association of viral load with CaCx,
whichwas supported both by non-parametricMann–WhitneyU test and
logistic regression analysis. This was also obvious, when viral load was
considered alongwith E2 disruption status. The logistic regressionmodel
(Table 1) justiﬁed the signiﬁcant role of both viral load and E2 disruption
status in the pathogenesis of CaCx under the impact of HPV16 infection.
Earlier, we reported that E2 disruption was signiﬁcantly higher among
CaCx cases compared to controls (Bhattacharjee and Sengupta, 2006a,b).
The present analysis, considering viral load as a risk factor of CaCx
development, also conﬁrmed the association of viral E2 disruption with
CaCx.
The intactness or disruption status of viral E2 gene concomitantwith
viral load thus appears to be relevant for HPV16 positive CaCx
pathogenesis. The biological plausibility of this observation is likely to
be supported by the fact that E2 protein enhances viral DNA replication
by interactingwith the viral replication factor E1 and recruiting it to the
origin of replication (Gillitzer et al., 2000; Berg and Stenlund, 1997;
Yasugi et al., 1997) and also plays a more direct role in replication
facilitating viral genome segregation by tethering the viral genomes to
host mitotic chromosomes (Jaquelline et al., 2006).
An attempt to predict the probability of disease risk on the basis of
the interplay of the signiﬁcantly associated viral factors like viral load
and E2 disruption status along with the individual's age revealed that
probability of CaCx increased with viral load irrespective of age and E2
status (Fig. 2A and B). Among individuals of similar age and viral load,
the probability of disease riskwas higher among those having disrupted
E2 than those with intact E2. It was also clear from such analysis that
among individuals having similar probability of disease risk, viral load
was higher among (i) those of lower age, irrespective of E2 status, and
(ii) among those of similar age but having intact E2. These observations
clearly justify the role of high HPV16 viral load in enhancing the risk of
CaCx and portray that attainment of high viral load could probably
complement the lack of E2 disruption in mediating cervical
carcinogenesis.
Our analysis also portrayed that viral load was signiﬁcantly higher
among CaCx cases harboring intact E2 (either purely intact or
concomitant) than among cases with purely disrupted E2. We observed
for the ﬁrst time in this study that copy number of viral isolates with
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E2 intact and disrupted) was signiﬁcantly lower compared to that within
CaCx cases harboring purely disrupted E2 only. We therefore speculate
that intact E2 inCaCxcasesmayberelevant fordiseasepathogenesis in the
absence of E2 disruption, or in the presence of reduced disruption of E2.
Hence there is a need to validate the hypothesis that another
complementary pathway of cellular transformation might exist, which
couldbemediated through ahigh viral load in the absence of or decreased
E2 disruption events.
Measurement of HPV16 load has long been suggested as a potential
tool to indicate severity of cervical neoplasia (Peitsaro et al., 2002),
showing increasing viral load from mild dysplasia to CaCx (Abba et al.,
2003; Hernandez-Hernandez et al., 2003; Josefsson et al., 2000) and our
study is in agreement with this, reﬂecting signiﬁcantly higher viral load
in CaCx cases compared to controls. However, some studies have failed
to identify higher viral loads in cervical dysplasia or cancer (Franco and
Coutlée, 2009), which could be attributable to a number of factors,
mainly the lack of standardized protocols in viral load estimation
(Saunier et al., 2008), different methods used for the calculation of viral
load (Roberts et al., 2008), study design, or samples tested (Wang and
Hildesheim, 2003) etc.
In this study, for estimation of viral load, we used Taqman-based
real-timePCR technique,which appears to be both sensitive and speciﬁc
(Häfner et al., 2008; Gallo et al., 2003) and interpreted viral copy
numbers present per 100 ng of input genomic DNA. In a randomly
selected subset of DNA samples (from both exfoliated cervical cells and
biopsy tissues),we estimated the copynumber of thehost geneG6PDby
a Taqman assay using 100 ng genomic DNA per assay. Such assay failed
to differ between the two sample types (data not shown), substantiating
the estimation of viral copy numbers present per 100 ng of genomic
DNA.We also generated titration curves of HPV16 viral load (natural log
transformed) covering a concentration range of 1–200 ng genomic DNA
(natural log transformed) for a randomly selected subset of DNA
samples from control scrapes as well as case biopsies. The curves were
linear in nature and the slopes were similar in all cases analyzed (data
not shown), suggesting that the nature of samples, whether cervical
scrapes or biopsy material, is unlikely to inﬂuence the viral load values
recorded as per the assay protocol followed by us.
It is worth noting that intact HPV16 E2 in the episomal form is often
found to coexistwith disrupted forms in CaCx (Matsukura et al., 1986),
often together with high viral load in such samples (Peitsaro et al.,
2002; Saunier et al., 2008; Kulmala et al., 2006), which is similar to our
observations. A few studies have also reported an increased frequency
of intact episomal HPV16 DNA in CaCx (Cullen et al., 1991).
Furthermore, existence of intact E2 in cervical cancer cell lines such
as CaSki or CC7T/IVGH (Choo et al., 1989) has also been observed. In
fact, some earlier studies have recorded the presence of episomal and
integrated HPV within the same cells in clinical samples conﬁrmed by
in situ hybridization (Cooper et al., 1991; Kristiansen et al., 1994).
Together, such observations justify our approach of analyzing viral
load in DNA samples harboring intact or disrupted E2, given the
possibility of the existence of both forms in CaCx tissues.
The prevailing concept regarding cervical carcinogenesis is in favor of
enhanced cellular proliferation following E2 disruption as a consequence
of viral integration, due towithdrawal of E2-induced repression of E6 and
E7 oncogenic transcription (Saunier et al., 2008; Kulmala et al., 2006;
Häfner et al., 2008). However, contradictory observations have also been
recorded, which revealed no signiﬁcant increase in E6 or E7 expression
following E2 disruption (Häfner et al., 2008; Cheung et al., 2008).
Furthermore, because of viral integration into the host genome leading to
chromosomal instability, the effectors of cellular transformation could
probably follow different pathways for different subgroups of CaCx
samples (Arias-Pulido et al., 2006; Kulmala et al., 2006; Gallo et al., 2003;
Duensing andMunger, 2002; Scheurer et al., 2007). A study (Kozuka et al.,
2000) based on SiHa and CaSki cell lines also proposed that high copy
number of HPVDNAwould directly contribute to increased expression ofE6 and E7. Some studies have identiﬁed a decrease in viral load with E2
disruption attributable to interruption of viral replication machinery
(Saunier et al., 2008; Kulmala et al., 2006) that depends on E1 and E2.
Taken together, these studies render strong biological plausibility to our
observation of high viral load in CaCx cases harboring intact E2, in
comparison to those harboring disrupted E2.
In conclusion, our exploratory analysis adds to the body of literature
that conﬁrms the signiﬁcant association of high viral loads with CaCx,
independent of other viral factors. Additionally, our approach further
highlights the signiﬁcance of viral load in CaCx pathogenesis in
association with age (high viral load at low age) and E2 status (high
viral load among E2 intact individuals).We have further identiﬁed for the
ﬁrst time thatCaCxcasesharboring intactHPV16E2gene(purely intact or
concomitant) are capable of mounting a high viral load overall, wherein
viral load of isolates with disrupted E2 among cases with concomitant
forms of E2 was signiﬁcantly lower, when compared to those harboring
disrupted E2 only. Such observations are likely to have signiﬁcant
implications in disease pathogenesis, probably by contributing to
sustained E6 and E7 expression. Based on the ﬁndings recorded in this
study, as well as our previous observations (Bhattacharjee and Sengupta,
2006a,b; Bhattacharjee et al., 2008),we reconﬁrm thatmultiple pathways
other than E2 disruption are likely to be instrumental in CaCx causation.
Materials and methods
Samples and subjects
The samples used for this study were nested to an ongoing natural
cohort study (Bhattacharjee and Sengupta, 2006a,b; Laikangbam et al.,
2007; Bhattacharya and Sengupta, 2007; Bhattacharjee et al., 2008). The
case samples (biopsy tissues)were collected frommarried womenwho
were attending a cancer referral hospital (Cancer CentreWelfare Home
and Research Institute, South 24 Parganas, West Bengal, India) during
the period 2000–2007. Out of a total of 300 malignant cervical samples
(tissue biopsies) collected during this period, 160 were identiﬁed to be
HPV16 positive, of which DNA samples from 152 were available for the
present analysis. These malignant samples were histopathologically
conﬁrmed as invasive squamous cell carcinomas and clinically diag-
nosed as tumor stage III and above as per FIGO classiﬁcation, and the age
of these women varied between 27 and 80 years of age (mean age:
49.60 years; S.D.: 11.06 years).
The control samples were normal cervical scrapes conﬁrmed by Pap
smear test and derived from married and non-pregnant (or, 6 months
post-partum) women with no previous history of cervical dysplasia/
malignancy. These women were attending a Reproductive Health (RH)
Clinic (Child in Need Institute or CINI, South 24 Parganas, West Bengal,
India), for routine reproductive healthcare counseling. Such samples
were also collected through cervical screening camps organized jointly
by CINI and us in the neighborhood villages from where women came
to attend the RH clinic. All the control sampleswere collectedwithin the
period of 1998–2007. Out of a total of 1112 cervical scrapes, 94
were identiﬁed to be HPV16 positive, of which 87 DNA samples were
available for the current analysis. The age of these 87 women
varied between 18 and 77 years (mean age: 33.52 years; S.D.:
11.014 years).
All samples, cases, and controlswere collected fromthe subjectswith
informed consent approved by the institutional ethical committee for
human experimentation. Details regarding subjects, samples, DNA
isolation, HPV screening and determination ofHPV16, and E2 disruption
status are described elsewhere (Laikangbam et al., 2007; Bhattacharjee
and Sengupta, 2006a).
Viral load estimation by real-time PCR of E6 gene
The quality and concentration of the stockDNA isolated fromHPV16
positive individuals (both cases and controls) was determined
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100 ng/µl were prepared by diluting the stock with TE buffer and
stored in aliquots at 4 °C to be used for subsequent PCRs. A primer pair
for β-globin gene, which ampliﬁes a 268-bp fragment, was used as
internal control, to ensure the integrity of the DNA samples (Tachezy et
al., 1994).
The DNA samples used for this study all portrayed the presence of β-
globin gene amplicon and viral load was expressed as viral copy
numbers present per 100 ng of genomic DNA. Quantitative Real-Time
PCR (qRT-PCR) was performed for viral load assessment following
absolute quantiﬁcationmethod using TAQMANhydrolysis probe on ABI
7900 HT Fast Real-Time PCR platform according to the method of
Peitsaro et al. (2002). The E6 oncogene is established as a relatively
stable viral gene. Therefore, a small region of E6 (81 bp: nucleotides 94
to 174) was targeted for this assay, keeping the qRT-PCR efﬁciency
around 100%. The PCR program was set with initial UNG activation at
50 °C for 2 min and denaturation at 95 °C for 10 min, followed by an
ampliﬁcation phase of 40 cycles each including two steps of denatur-
ation and annealing at 95 °C for 15 s and 60 °C for 1 min, respectively.
Hundred nanograms of HPV16 positive genomic DNA was targeted for
qRT-PCR in a reaction mixture of 20 µl containing 25 ng of primers
(forward: 5'-GAGAACTGCAATGTTTCAGGACC-3'; reverse: 5'-TGTA-
TAGTTGTTTGCAGCTCTGTGC-3') and 0.1 µM of hydrolysis probe [(6-
FAM)-CAGGAGCGACCCAGAAAGTTACCACAGTT-(DQ)] (Peitsaro et al.,
2002) in Taqman Universal Master Mix (P.E. Applied Biosystems,
Perkin-Elmer). A standard curve, plot (R2=0.99) of threshold cycles
(CT) against log copy number, was generated using serial dilutions of
1.75×109, 1.75×107, 1.75×105, and 1.75×103 copies of the HPV16
plasmid insert (pUC 19 plasmid vector with HPV16 ref. sequence
insert=10.582 kb; concentration=20×103 ng/μl) along with 100 ng
genomic DNA (placental DNA). Viral copy number per 100 ng of
genomic DNAwas calculated by the following formula andwas then log
transformed (natural log):
Number of copies per μl=(amount of plasmid in grams) ÷
(weight of one molecule of plasmid in grams)=1.75×1012
copies=1.75×1012 copies/μl
[Amount of plasmid in grams=20×103×10−9]
[1 kb of double stranded DNA=6.5×105 Daltons; Avogadro's
number=6.023×1023; 1 Dalton=(1/6.023×1023) g]
[Weight of one molecule of plasmid
in grams=10.582×6.5×105/6.023×1023]
Three non-template controls (NTCs) were used in each assay to
exclude the chances of non-speciﬁc ampliﬁcation. The viral copy
number values (per 100 ng of genomic DNA) of the unknown samples
were interpreted from the standard curve, which showed a linear
relationship between the threshold cycle values plotted against the
log of the copy number over the entire range of dilutions. The slope of
the standard curve was used to determine the efﬁciency [Efﬁcien-
cy=10(−1/slope)−1] of the PCR reaction. An assay in which 90–100%
efﬁciency was obtained was considered for analysis. Each such assay
was done at least twice, with three replicates per sample in each
assay.
Estimation of E2 copy number and determination of E2/E6 ratios of the
copy numbers by real-time PCR
In general, disruption of E2 gene releases the repressive effect of E2
protein on viral oncogene (E6 and E7) expression, leading to host cellular
transformation. The most commonly reported (Kalantari et al., 2001;Saunier et al., 2008; Arias-Pulido et al., 2006; Kulmala et al., 2006) region
that harbors the majority of disruption events within HPV16 E2 gene is
the one that codes for the hinge of the E2 protein. A small portion
(nucleotides 3361 to 3442; 82 bp) of this region was targeted to
determine the presence and copy number of the E2 gene by qRT-PCR
(Peitsaro et al., 2002) keeping efﬁciency of the assay around 100%. One
hundred nanograms of HPV16 positive genomic DNA was used as
template DNA in a reaction mixture of 20 µl containing 25 ng of primers
(forward: 5'-AACGAAGTATCCTCTCCTGAAATTATTAG-3'; reverse: 5'-
CCAAGGCGACGGCTTTG-3') and 0.1 µM of hydrolysis probe [(6-VIC)-
CACCCCGCCGCGACCCATA-(DQ)] in Taqman Universal Master Mix (P.E.
Applied Biosystems, Perkin-Elmer). The PCR program used and the
method of estimation of E2 copy number was the same as that used for
viral E6 copy number estimation. Copy numbers of E2 were determined
from the standard plot (R2=0.98), whichwas obtained in the sameway
as in case of qRT-PCR of E6, and log transformed (natural log). E2/E6
ratios were subsequently determined for each of the samples analyzed.
Conﬁrmation of the disruption status of E2 gene
Samples were considered as having intact E2 only when
ampliﬁcation was recorded with real-time PCR for E2 as described
above, and (i) PCR for the larger fragment of E2 (nucleotides 2811–
3837; amplicon size 1027 bp) and (ii) PCR with three sets of
overlapping primer pairs spanning nucleotides 2810–3471, 3448–
3649, and 3596–3872, yielding amplicon sizes of 661, 203, and 277
base pairs, respectively, in three separate reactions. The latter PCR
protocols have been published earlier from our laboratory (Bhatta-
charjee and Sengupta, 2006a,b). The samples that failed to amplify the
larger E2 fragment as well as one or more of the overlapping
fragments, irrespective of real-time PCR-based ampliﬁcation of E2,
were considered to harbor purely disrupted E2.
Statistical analyses
Box plots were constructed to observe the difference in distribution
of viral load among cases and controls. Kolmogorov–Smirnov test
identiﬁed viral load (copy number of viral genome per 100 ng of HPV16
positive genomic DNA) as a variable not following normal distribution.
Therefore, non-parametric test (Mann–Whitney U test) was performed
to study association of viral load with the disease phenotype. Logistic
regression analysis was carried out to determine the association of viral
copy numberswithCaCx. To investigate the individual risk factor effects,
we have included the viral factors, viz. copy numbers and E2 disruption
status in the logistic regression model, adjusting the possible effect of
age. The signiﬁcance of the effects of the individual risk factors or
covariates is determined in terms of OR (95% CI) and p-values.
Based on such logistic regression models, probability-prediction
graphs for disease risk were constructed against viral load at
different ages of individuals considering E2 intact and E2 disrupted
viral genome statuses as covariates. All statistical analyseswere done
using software packages SPSS (version 16.0 for windows) and R
(www.r-project.org).
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